CVS Health (CVS) announced it will support simpler access to more affordable fertility treatments for all Americans through its CVS Specialty Pharmacy and make it easier to pick up fertility medication at its 9,000 community pharmacy locations. CVS Specialty Pharmacy will be a core partner in the TrumpRx Fertility program. As the Trump Administration continues to establish more competitive prices for important medicines, the Administration has engaged with EMD Serono, manufacturer of Gonal-F an in-vitro fertilization drug to bring the price of the medicine down by 84%. The company said it anticipates the program will be available in January 2026. “Fertility medications often require special administration and high-touch expertise. We are proud to join the President to help make every step of the journey as simple as possible for families by providing nationwide access,” said Lucille Accetta, RPh, Senior Vice President and Chief Pharmacy Officer, CVS Health. “We are committed to being America’s most trusted health care company as we strive to continually improve affordability and access to medicine for families everywhere.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Pharmacy completes acquisition of Rite Aid assets nationwide
- UnitedHealth Stock (UNH) Scores Goldman Sachs’ Buy Rating, Truist Lifts Price Target
- AMD upgraded, Micron downgraded: Wall Street’s top analyst calls
- CVS Health price target raised to $92 from $84 at Truist
- CVS Health price target raised to $89 from $82 at Morgan Stanley